 Hutchmed China Limited NASDAQ: HCM announces the first commercial sale in China of Orpathys savolitinib, a selective small-molecule inhibitor of MET, a receptor tyrosine kinase. It follows less than three weeks after the approval of Orpathys in China to treat patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping alterations, who have progressed following prior systemic therapy or are unable to receive chemotherapy. 